DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On July13, 2017, Depomed,Inc. (the “Company”) announced its intent to effect a refinancing of its existing $375 million principal amount of privately placed secured senior notes and issued a press release announcing selected preliminary financial information for the quarter ended June30, 2017. The press release is attached hereto as Exhibit99.1 and is incorporated by reference herein. The preliminary financial information as of June30, 2017 has not been reviewed by the Company’s auditors and is subject to change upon completion of the accounting and financial reporting processes necessary to complete the Company’s financial closing procedures. The preliminary financial information is not a comprehensive statement of the Company’s financial results for the quarter ended June30, 2017, and the Company’s actual results may differ materially from this estimate as a result of the completion of the Company’s financial closing procedures, final adjustments and other developments arising between now and the time that the Company’s financial results for this period are finalized.

The information in Item 2.02 of this Current Report on Form8-K shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Depomed,Inc. Press Release issued on July13, 2017


DEPOMED INC Exhibit
EX-99.1 2 a17-17905_1ex99d1.htm EX-99.1 Exhibit 99.1     Depomed Announces Intent to Effect a Debt Refinancing   Provides Selected Preliminary Second Quarter 2017 Financial Results and Reconfirms Full Year Financial Guidance   NEWARK,…
To view the full exhibit click here

About DEPOMED,INC. (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.